FRANKFURT: Bayer AG struck an US$875mil deal to acquire British women’s health biotech Kandy Therapeutics Ltd in a move to expand its pharmaceuticals division before the expiration of patents on existing medicines.
The German drug and chemical company agreed to pay US$425mil upfront and potential milestone payments of US$450mil until the launch of Kandy’s experimental treatment for menopause symptoms.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
